Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update

Journal of Urology

Volumn 178, Issue 6, 2007, Pages 2314-2330

  Hall, M Craig ^a   Chang, Sam S ^a   Dalbagni, Guido ^a   Pruthi, Raj Som ^a   Seigne, John Derek ^a   Skinner, Eila Curlee ^a   Wolf Jr , J Stuart ^a   Schellhammer, Paul F ^a  

^a American Urological Association   (United States)

Author keywords

bacillus Calmette Gu rin; mitomycin C; practice guideline; transurethral resection of bladder tumor; urinary bladder neoplasms

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RESEARCH; CANCER STAGING; EARLY CANCER; HUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 36049006136     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.003     Document Type: Article

References (78)

1. Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta
2. Smith Jr. J.A., Labasky R.F., Cockett A.T., Fracchia J.A., Montie J.E., and Rowland R.G. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J Urol 162 (1999) 1697
3. Oosterlinck W, van der Meijden A, Sylvester R, Böhle A, Rintala E, Solsona Narvón E et al: Guidelines on TaT1 (non-muscle invasive) bladder cancer. http://www.uroweb.org/nc/professional-resources/guidelines/online/. Accessed September 4, 2007.
4. Shelfo S.W., Brady J.D., and Soloway M.S. Transurethral resection of bladder cancer. Atlas Urol Clin North Am 5 (1997) 1
5. Koch M.O., and Smith Jr. J.A. Natural history and surgical management of superficial bladder cancer (stages Ta/T1/CIS). In: Vogelzang N.J., Debruyne F.M., Shipley W.U., and Scardino P. (Eds). Comprehensive Textbook of Genitourinary Oncology (1996), Lippincott Williams & Wilkins, Baltimore 405-415 chapt 26
6. Smith Jr. J.A. Endoscopic applications of laser energy. Urol Clin North Am 13 (1986) 405
7. Soloway M.S., Bruck D.S., and Kim S.S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170 (2003) 438
8. Donat S.M., North A., Dalbagni G., and Herr H.W. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 171 (2004) 636
9. Gofrit O.N., Pode D., Lazar A., Katz R., and Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49 (2006) 303
10. Bouffioux C., Kurth K.H., Bono A., Oosterlinck W., Kruger C.B., DePauw M., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934
11. Tolley D.A., Parmar M.K., Grigor K.M., Lallemand G., Benyon L.L., Fellows J., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233
12. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186
13. De Boer E.C., De Jong W.H., Steerenberg P.A., Aarden L.A., Tetteroo E., De Groot E.R., et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 34 (1992) 306
14. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124
15. Huncharek M., Geschwind J.F., Witherspoon B., McGarry R., and Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53 (2000) 676
16. Huncharek M., McGarry R., and Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21 (2001) 765
17. Shelley M.D., Kynaston H., Court J., Wilt T.J., Coles B., Burgon K., et al. A systemtic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88 (2001) 209
18. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964
19. Messing E.M., and Catalona W. Urothelial tumors of the urinary tract. In: Walsh P.C., Retik A.B., Vaughan Jr. E.D., and Wein A.J. (Eds). Campbell's Urology. 7th ed. (1998), WB Saunders, Philadelphia 2327-2408 chapt 77
20. Hudson M.A., and Herr H.W. Carcinoma in situ of the bladder. J Urol 153 (1995) 564
21. Lamm D.L. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology 9 (1995) 947
22. van der Meijden A.P., Sylvester R., Oosterlinck W., Solsona E., Boehle A., Lobel B., et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48 (2005) 363
23. Torti F.M., Shortliffe L.D., Williams R.D., Pitts W.C., Kemspon R.L., Ross J.C., et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6 (1988) 476
24. Stricker P., Pryor K., Nicholson T., Goldstein D., Golovsky D., Ferguson R., et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 48 (1996) 857
25. Mohanty N.K., Malhotra V., Nayak R.L., and Arora R.P. Combined low dose intravesical immuno-therapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J Chemother 14 (2002) 194
26. Lam J.S., Benson M.C., O'Donnell M.A., Sawczuk A., Gavazzi A., Wechsler M.H., et al. Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21 (2003) 354
27. Joudi F.N., Smith B.J., O'Donnell M.A., and National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344
28. Koontz Jr. W.W., Prout Jr. G.R., Smith W., Frable W.J., and Minnis J.E. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J Urol 125 (1981) 307
29. Kurth K., Vijgh W.J., tenKate F., Bogdanowicz J.F., Carpentier P.J., and Van Reyswoud I. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J Urol 146 (1991) 1508
30. Oosterlinck W., Kurth K.H., Schroder F., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749
31. Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., and Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163 (2000) 761
32. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., et al. Gemcitabine and cisplastin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic blader cancer: results of a large, randomized multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068
33. Bartoletti R., Cai T., Gacci M., Giubilei G., Viggiani F., Santelli G., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66 (2005) 726
34. Mattioli F., Curotto A., Manfredi V., Gosmar M., Garbero C., Ambruosi C., et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharacokin- etic study. Anticancer Res 25 (2005) 2493
35. Dalbagni G., Russo P., Bochner B., Ben-Porat L., Sheinfeld J., Sogani P., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24 (2006) 2729
36. Hendricksen K., and Witjes J.A. Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 16 (2006) 361
37. Eddy D.M. The confidence profile method: a Bayesian method for assessing health technologies. Oper Res 37 (1989) 210
38. Eddy D.M., Hasselblad V., and Shachter A. A Bayesian method for synthesizing evidence. The Confidence Profile Method. Int J Technol Assess Health Care 6 (1990) 31
39. Burnand K.G., Bovd P.J., Mavo M.E., Shuttleworth K.E., and Lloyd-Davies R.W. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 48 (1976) 55
40. Zincke H., Utz D.C., Taylor W.F., Myers R.P., and Leary F.J. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 129 (1983) 505
41. Oosterlinck W., Kurth K.H., Schröder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749
42. Tolley D.A., Parmar M.K., Grigor K.M., Lallemand G., Benyon L.L., Fellows J., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233
43. Solsona E., Iborra I., Ricós J.V., Monrós J.L., Casanova J., and Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161 (1999) 1120
44. Ali-el-Dein B., Nabeeh A., el-Baz M., Shamaa S., and Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79 (1997) 731
45. Tolley D.A., Hargreave T.B., Smith P.H., Williams J.L., Grigor K.M., Parmar M.K., et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 296 (1988) 1759
46. Huncharek M., and Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 27 (2004) 522
47. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86
48. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90
49. Au J.L., Badalament R.A., Wientjes M.G., Young D.C., Warner J.A., Venema P.L., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597
50. Tsushima T., Matsumura Y., Ozaki Y., Yoshimoto J., and Ohmori H. Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer. Cancer Chemother Pharmacol 20 (1987) s72
51. Hirao Y., Okajima E., Ohara S., Ozono S., Hiramatsu T., Yoshida K., et al. Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother Pharmacol 20 (1987) s85
52. Huland H., and Otto U. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. Eur Urol 9 (1983) 84
53. Akaza H., Koiso K., Kotake T., Matsumura Y., Isaka S., Machida T., et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 30 (1992) s15
54. Krege S., Giani G., Meyer R., Otto T., and Rübben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol 156 (1996) 962
55. Badalament R.A., Herr H.W., Wong G.Y., Gnecco C., Pinsky C.M., Whitemore Jr. W.F., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 5 (1987) 441
56. Hudson M.A., Ratliff T.L., Gillen D.P., Haaff E.O., Dresner S.M., and Catalona W.J. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 138 (1987) 295
57. Palou J., Laguna P., Millán-Rodríguez F., Hall R.R., Salvador-Bayarri J., and Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488
58. Han R.F., and Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials. Urology 67 (2006) 1216
59. Lamm D.L., Blumenstein B.A., Crawford E.D., Crissman J.D., Lowe B.A., Smith Jr. J.A., et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group study. Urol Oncol 1 (1995) 119
60. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682
61. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., and Mason M.D. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485
62. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186
63. Lundholm C., Norlén B.J., Ekman P., Jahnson S., Lagerkvist M., Lindeborg T., et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156 (1996) 372
64. Dutta S.C., Smith Jr. J.A., Shappell S.B., Coffey C.S., Chang S.S., and Cookson M.S. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490
65. Schwaibold H.E., Sivalingam S., May F., and Hartung R. The value of second transurethral resection for T1 bladder cancer. BJU Int 97 (2006) 1199
66. Brauers A., Buettner R., and Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy of ten too early?. J Urol 165 (2001) 808
67. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296
68. May M., Nitzke T., Helke C., Vogler H., and Hoschke B. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol 38 (2004) 231
69. Bianco Jr. F.J., Justa D., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22 (2004) 290
70. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666
71. Hassan J.M., Cookson M.S., Smith Jr. J.A., Johnson D.L., and Chang S.S. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol 172 (2004) 882
72. Kurth K.H., Denis L., Bouffioux C., Sylvester R., Debruyne F.M., Pavone-Macaluso M., et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A (1995) 1840
73. Parmar M.K., Freedman L.S., Hargreave T.B., and Tolley D.A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 143 (1989) 284
74. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., and Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685
75. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466
76. de Reijke T.M., Kurth K.H., Sylvester R.J., Hall R.R., Brausi M., van de Beek K., et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma of the bladder: results of a European Organization for the Research and Treatment of Cancer - Genito-Urinary Group Phase III Trial (30906). J Urol 173 (2005) 405
77. Catalona W.J., Hudson M.A., Gillen D.P., Andriole G.L., and Ratliff T.L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137 (1987) 220
78. CONSORT guidelines. http://www.consort-statement.org. Accessed September 4, 2007.